Metastatic Melanoma: Not Quite Curable…But Getting There


By 2050, the number of deaths due to malignant melanoma in the U.S. could be three times lower than peak levels reached before 1960. Researchers presented the data behind this prediction at the 2017 European Cancer Congress in January.

It is unclear how much of this anticipated decline in deaths can be attributed to the availability of new, effective treatments. However, it is obvious that much-increased awareness of sunlight exposure as the single factor most responsible for the development of skin melanoma has contributed to lower incidence of the disease.

In any case, the armament of treatments available for metastatic melanoma is currently such that this diagnosis has transformed from being almost universally fatal (even just a few years ago) into a being largely treatable. Since 2011, the U.S. Food and Drug Administration (FDA) has approved eight new drugs for melanoma.

Now, the pressing questions are: Why do these drugs not work for all patients? How can doctors select which patients should be treated with different types of drugs (targeted versus immune checkpoint versus intralesional)? And how can doctors identify patients who may benefit from a combination of different drugs?

BRAF-mutant melanoma: targeted drugs 

Getting a positive test for the BRAF V600 tumor mutation is certainly good news for a newly diagnosed melanoma patient. This is because some targeted drugs work very well against such tumors, which account for about 50% of melanomas.

The drugs vemurafenib or dabrafenib, which attack tumors by inhibiting mutant BRAF proteins, are no longer used on their own because combining them with MEK inhibitors (cobimetinib and trametinib, respectively) works so much better. The percentage of patients who respond to combined BRAF/MEK inhibition is about 70% or higher, and durable complete responses were observed in about 19% patients with stage IV or unresectable stage III melanoma in three large clinical trials that tested these combinations. The results of treatment with dabrafenib and trametinib in patients with resectable stage III melanoma were particularly impressive. One hundred percent of these patients had no relapse within the first six months after treatment, compared to just 28% of those treated with standard chemotherapy. All patients had fewer than three metastatic sites.

That last point brings us to an important question: Which stage IV patients with BRAF-mutant (BRAF+) melanoma may need a combined treatment with targeted and immunotherapy (immune checkpoint) drugs?

It is becoming clear that stage IV patients who have fewer, less bulky metastases (lower tumor burden) do much better on BRAF/MEK-targeting drugs. High blood levels of a protein called LDH has long been recognized as a poor prognostic factor in melanoma, and it has not lost its grim significance in the era of targeted and immunotherapy drugs. Patients with high LDH and many metastatic tumors may need a combined treatment with BRAF/MEK inhibitors and immune checkpoint drugs.

So far, combination treatments have proven to be efficacious in patients with high tumor burden. The problem is that combining BRAF/MEK inhibitors with immune checkpoint drugs of the type known as anti-PD-1 increases side effects (toxicity) in quite a dramatic way. The Keynote 022 clinical trial—which combined the anti-PD-1 drug pembrolizumab with dabrafenib and trametinib in a small group of patients—reported that 40% experienced serious side effects (grade 3–4), and close to 30% discontinued treatment. A response rate of 60% was observed but remains to be confirmed.

A very similar rate of side effects was observed in a trial that combined atezolizumab (another immune checkpoint drug of the type known as anti-PD-L1) with vemurafenib and cobimetinib. On a highly positive note, 83% of the patients in this trial responded to the treatment, with 10% going into complete remission. An earlier study of durvalumab (also anti-PD-L1) with dabrafenib and trametinib saw responses in 69% of patients.

Several trials have also addressed the possibility of sequential treatment with two different types of drugs in order to address the problem of toxicity.

Immune checkpoint drugs across the molecular subtypes

Immune checkpoint drugs may also be effective in tumors with mutations other than BRAF, including a mutation in the NRAS gene (NRAS+). Data are being accumulated for patients receiving the FDA-approved immunotherapy drugs nivolumab or pembrolizumab (both anti-PD-1 drugs). It appears that 47% of patients receiving nivolumab survive for three years, and 48–49% of those receiving pembrolizumab survive for 2 years (pembrolizumab data have not yet reached the 3-year point). Combination of nivolumab and ipilimumab (a type of immune checkpoint drug known as an anti-CTLA4 antibody) could eventually produce better results, but at the cost of a much higher toxicity. It is a bit difficult to say if these data are similar for BRAF+ and BRAF-/NRAS+ melanoma patients receiving immune checkpoint drugs, because most patients with BRAF+ cancers receive targeted drugs.

NRAS-mutant melanoma

Patients whose tumors test positive for an NRAS mutation (NRAS+) but not for a BRAF mutation (BRAF-) certainly have fewer treatment options than those whose tumors are BRAF-positive. NRAS mutations are encountered in about 20% of melanomas, and there are no effective targeted drugs for this subgroup. The only targeted drug that has shown promise in NRAS+ melanoma is binimetinib, a MEK inhibitor. In a trial for patients who were either untreated or had not responded to immune checkpoint drugs, binimetinib produced responses in 45% of patients; of those receiving only dacarbazine, a standard chemotherapy, just 9% responded. However, binimetinib prolonged overall survival by just 1.3 months compared to dacarbazine—not exactly an impressive improvement, which is apparently why the manufacturer of binimetinib withdrew its application for FDA approval of the drug.

Other trials are testing immune checkpoint drugs combined with MEK inhibitors for patients whose melanomas have no BRAF mutations (of which a substantial proportion have mutated NRAS). No results of these trials have yet been reported. Meanwhile, a very small study reported a response rate of 45% to combination of atezolizumab (anti-PD-L1) and cobimetinib in BRAF- melanoma patients. Additional trials testing durvalumab or pembrolizumab with trametinib have not posted results yet.

Regardless of specific tumor mutations, much hope lies in the clinical exploration of combinations of drugs that activate the immune system in different ways. Numerous immune checkpoint drugs work by activating the immune system. However, unlike the anti-PD-1 and anti-CTLA4 drugs discussed above, which remove inhibitory signals from the immune system’s T cells so they can attack cancer cells, newer drugs actually activate T cells by binding to positive regulatory proteins on these cells. Other new drugs aim to eliminate inhibitory signals created in the tumor microenvironment, such as those produced by different types of inflammatory cells or regulatory T cells. I would refer the interested reader to this excellent overview of these new drugs, which are now being tested against metastatic melanoma in numerous phase I trials.


Pembrolizumab Affords Long-Term Survival to One-Fourth of Selected Patients With NSCLC, Alternative Statistical Model Suggests

Excerpt:

“Statistical modeling of long-term survival from the KEYNOTE trials of the programmed cell death protein 1 (PD-1)–inhibitor pembrolizumab ­(Keytruda) estimates that one-quarter of appropriately selected patients with advanced non–small cell lung cancer (NSCLC) may attain long-term survival.

” ‘In the context of the pembrolizumab program, these are the furthest-out data that we have so far, and I think they represent a remarkable step forward,’ commented Matthew D. Hellmann, MD, of Memorial Sloan Kettering Cancer Center, New York, who presented the analysis at the 2017 ASCO-SITC (Society for Immunotherapy of Cancer) Clinical Immuno-Oncology Symposium.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Clinical Trials Test Treatments for High-Grade Brain Tumors


With a few exceptions, glioblastoma (GBM) remains largely incurable, and the U.S. Food and Drug Administration (FDA) has approved few treatments for the disease. Surgery (when feasible), radiation, and temozolomide are used in most patients. But even if a newly diagnosed tumor can be surgically excised, recurrences are too common.

In this blog post, I simply list some of the new treatments available in clinical trials for GBM and other high-grade brain tumors. Only drugs that have at least some preliminary results of activity are included, and the list is not meant to be fully comprehensive. The interested reader can judge for herself what might be of interest, keeping in mind that no single treatment is suitable or will work for all GBM patients. Continue reading…


Scientists Discover Why Some Cancers May Not Respond to Immunotherapy

Excerpt:

UCLA scientists have discovered that people with cancers containing genetic mutations JAK1 or JAK2, which are known to prevent tumors from recognizing or receiving signals from T cells to stop growing, will have little or no benefit from the immunotherapy drug pembrolizumab. This early-stage research has allowed them to determine for the first time why some people with advanced melanoma or advanced colon cancer will not respond to pembrolizumab, an anti-PD-1 treatment.

“The study, led by Dr. Antoni Ribas, director of the UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program, also found that JAK1 or JAK2 genetic mutations led to a loss of reactive PD-L1 expression.  PD-L1 is an immune biomarker expressed on tumor cells and pembrolizumab requires an abundance of it to effectively attack cancer cells.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Super Patient: Peter Fortenbaugh Faces the Uncertainty of Pioneering Melanoma Treatment


In spring of 2014, Peter Fortenbaugh noticed what appeared to be a tick that had bitten his lower calf. “It turned out not to be a tick, but it didn’t really go away,” he says.

The spot began to grow and bulge, and in October, Peter showed it to his primary care doctor, who referred him to a dermatologist to remove it. At the time, Peter recalls, it did not occur to him that the growth could be serious.

“I was actually very concerned about skin cancer because I spent a lot of time out in the sun sailing,” Peter says. “I put on a tremendous amount of sunscreen and protection, but never on my legs…I never connected the dots.”

However, a biopsy of the growth came back positive for melanoma. Peter, who lives in Palo Alto, California, with his wife and three children, immediately reached out to several doctors in the San Francisco Bay Area, and all had the same advice: “Take it out, take a biopsy.” Continue reading…


Avelumab Shows Promise as Frontline Immunotherapy Alternative in NSCLC

Excerpt:

“Immunotherapy is quickly becoming a mainstay in the frontline setting for the treatment of patients with metastatic non–small cell lung cancer (NSCLC).

“In October 2016, the FDA approved the PD-1 inhibitor pembrolizumab (Keytruda) as a first-line treatment for patients with metastatic NSCLC whose tumors have at least 50% PD-L1 expression and who do not harbor EGFR or ALK mutations.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


FDA Grants Priority Review to Keytruda in Combination with Chemotherapy for Advanced NSCLC

Excerpt:

“The FDA granted priority review to a supplemental biologics license application for pembrolizumab in combination with chemotherapy for first-line treatment of patients with metastatic, nonsquamous non–small cell lung cancer, according to the drug’s manufacturer.

“The application seeks approval of pembrolizumab (Keytruda, Merck), an anti–PD-1 therapy, in combination with pemetrexed and carboplatin regardless of patients’ PD-L1 expression, provided they have no EGFR or ALK mutations.

“The FDA is expected to make a decision by May 10.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab)

Excerpt:

“Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of epacadostat, Incyte’s investigational oral selective IDO1 inhibitor, with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

“With the expansion of the clinical development program, the companies plan to initiate pivotal studies of epacadostat in combination with KEYTRUDA in four additional tumors:  non-small cell lung cancer, renal cell carcinoma, bladder cancer and squamous cell carcinoma of the head and neck. Presentations of data from the ongoing studies of epacadostat in combination with KEYTRUDA, which support this decision, are expected at upcoming medical meetings.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck’s KEYTRUDA® (pembrolizumab) and Eisai’s HALAVEN® (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer

Excerpt:

“Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new interim data investigating Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in combination with Eisai’s microtubule dynamics inhibitor, HALAVEN® (eribulin) in patients with metastatic triple-negative breast cancer (TNBC). Findings presented during the 2016 San Antonio Breast Cancer Symposium (SABCS) were based on interim data from 39 evaluable patients and showed an overall response rate (ORR) of 33.3% (n=13/39; 95% CI, 19.5-48.1), with one complete response and 12 partial responses (Abstract #: P5-15-02). ORR was similar between PD-L1-positive and -negative cohorts [PD-L1 positive=29.4% (n=5/17; 95% CI, 11.1-51.1); PD-L1 negative=33.3% (n=6/18; 95% CI, 14.1-54.6)]. HALAVEN and KEYTRUDA are not approved for use in combination.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.